Patients with severe facial palsy (grades IV–VI according HB) revealed higher levels of the CSF cytokine TNFSF13, and clinical outcome after 3 months was less favorable at higher levels of the CSF cytokine Fractalkine. This evidence concerns the gene CSF2 and Facial palsy.